Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain genetic risk factors and Parkinson’s progression.
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for the Parkinson’s community.
April marks World Parkinson’s Awareness Month to highlight the condition that affects some seven to 10 million people globally. At the centre of this month is World Parkinson’s Day on 11 April.
On 5 May, Cure Parkinson’s supporter Jane Birkin will begin her 5-50-500 TRYathlon, a fundraising challenge she created to mark her 50th birthday!
Can meeting the needs of women living with Parkinson’s unlock new treatments to better manage, slow, stop or even cure Parkinson’s? Re-watch our recent webinar.